舒泰神(300204)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

300204 舒泰神

已收盘 02-06 15:00:00

{"stockData":{"symbol":"300204","market":"SZ","secType":"STK","nameCN":"舒泰神","latestPrice":27.82,"timestamp":1770361395000,"preClose":27.45,"halted":0,"volume":42376842,"delay":0,"changeRate":0.0135,"floatShares":454000000,"shares":478000000,"eps":-0.3478,"marketStatus":"已收盘","change":0.37,"latestTime":"02-06 15:00:00","open":27.72,"high":29.77,"low":27,"amount":1204000000,"amplitude":0.1009,"askPrice":27.83,"askSize":91,"bidPrice":27.82,"bidSize":677,"shortable":0,"etf":0,"ttmEps":-0.3478,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1770600600000},"marketStatusCode":5,"adr":0,"adjPreClose":27.45,"symbolType":"stock","openAndCloseTimeList":[[1770341400000,1770348600000],[1770354000000,1770361200000]],"highLimit":30.2,"lowLimit":24.71,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":477772555,"isCdr":false,"pbRate":15.06,"roa":"--","roe":"--","epsLYR":-0.3,"committee":0.374374,"marketValue":13292000000,"turnoverRate":0.0934,"status":0,"floatMarketCap":12621000000},"requestUrl":"/m/hq/s/300204","defaultTab":"news","newsList":[{"id":"2609983588","title":"股市必读：舒泰神（300204）2月5日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2609983588","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609983588?lang=zh_cn&edition=full","pubTime":"2026-02-06 01:19","pubTimestamp":1770311948,"startTime":"0","endTime":"0","summary":"截至2026年2月5日收盘，舒泰神报收于27.45元，上涨0.96%，换手率6.03%，成交量27.35万手，成交额7.57亿元。注射用STSP-0601在伴抑制物血友病A或B患者出血按需治疗方向登记号为CTR20250843的III期临床试验正在正常推进中。有关研发项目进展，敬请关注CDE平台公示、后续定期报告及项目进展公告。当日关注点来自交易信息汇总：2月5日主力资金净流入1415.69万元，呈现明显吸筹迹象。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020600001249.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0046","BK0028","300204"],"gpt_icon":0},{"id":"2609370643","title":"舒泰神：注射用STSP-0601III期临床试验正在正常推进中","url":"https://stock-news.laohu8.com/highlight/detail?id=2609370643","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609370643?lang=zh_cn&edition=full","pubTime":"2026-02-05 20:48","pubTimestamp":1770295711,"startTime":"0","endTime":"0","summary":"证券之星消息，舒泰神(300204)02月05日在投资者关系平台上答复投资者关心的问题。投资者提问：广生堂今天公告完成三期临床全部受试者入组，贵司0601受试者是不是还没招满人？舒泰神回复：您好！注射用STSP-0601在伴抑制物血友病A或B患者出血按需治疗方向登记号为CTR20250843的III期临床试验正在正常推进中。有关研发项目进展，敬请关注CDE平台公示、后续定期报告及项目进展公告。感谢您对公司的关注，谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020500037506.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0239","300204","BK0028"],"gpt_icon":0},{"id":"2608885030","title":"股市必读：舒泰神（300204）1月30日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2608885030","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608885030?lang=zh_cn&edition=full","pubTime":"2026-02-02 01:49","pubTimestamp":1769968148,"startTime":"0","endTime":"0","summary":"截至2026年1月30日收盘，舒泰神报收于25.66元，上涨0.63%，换手率3.36%，成交量15.26万手，成交额3.95亿元。董秘最新回复投资者： 0601资料准备的怎么样了？什么时候提交董秘： 您好！公司生产经营活动正常，并通过加强已上市品种的营销工作、银行贷款及推动定增等多途径增强现金储备。公司正按照发补通知要求组织相关部门落实并尽快补充提交相关材料，继续推进注射用STSP-0601附条件批准上市工作。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020200000845.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0239","BK0046","300204"],"gpt_icon":0},{"id":"2607094591","title":"舒泰神：公司生产经营活动正常","url":"https://stock-news.laohu8.com/highlight/detail?id=2607094591","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607094591?lang=zh_cn&edition=full","pubTime":"2026-01-30 15:33","pubTimestamp":1769758393,"startTime":"0","endTime":"0","summary":"证券之星消息，舒泰神01月30日在投资者关系平台上答复投资者关心的问题。公司生产经营活动正常，并通过加强已上市品种的营销工作、银行贷款及推动定增等多途径增强现金储备。公司与银行签订借款合同是为了保障公司日常生产经营及补充公司流动资金需求，预期会对公司生产经营产生积极的影响，有利于公司的平稳发展。公司2025年度向特定对象发行股票事项正在有序推进中。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026013000020792.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","300204","BK0239","BK0046"],"gpt_icon":0},{"id":"2606799365","title":"舒泰神最新公告：预计2025年净利润亏损6981.35万元-8532.76万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2606799365","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606799365?lang=zh_cn&edition=full","pubTime":"2026-01-28 16:52","pubTimestamp":1769590366,"startTime":"0","endTime":"0","summary":"舒泰神(300204.SZ)公告称，舒泰神预计2025年归属于上市公司股东的净利润为-8532.76万元至-6981.35万元，上年同期为-14484.26万元。业绩变动原因：苏肽生销售收入及销量略有增长；舒泰清收入下降，公司正多渠道拓展舒泰清及聚乙二醇类新产品营销。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012800028393.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300204"],"gpt_icon":0},{"id":"2601764978","title":"1月7日舒泰神现3笔折价10.04%的大宗交易 合计成交1326.5万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2601764978","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601764978?lang=zh_cn&edition=full","pubTime":"2026-01-07 17:32","pubTimestamp":1767778336,"startTime":"0","endTime":"0","summary":"证券之星消息，1月7日舒泰神发生大宗交易，交易数据如下：近三个月该股共发生5笔大宗交易，合计成交3.8万手，折价成交5笔。该股近期无解禁股上市。截至2026年1月7日收盘，舒泰神(300204)报收于29.49元，上涨2.25%，换手率7.23%，成交量32.82万手，成交额9.6亿元。该股近半年内有股东持股变动，合计净减持1285.15万股，股东增减持明细如下表：该股最近90天内无机构评级。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010700026950.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0028","300204","BK0239"],"gpt_icon":0},{"id":"2601878858","title":"舒泰神：预计2026年1月31日前发布2025年年度业绩预告","url":"https://stock-news.laohu8.com/highlight/detail?id=2601878858","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601878858?lang=zh_cn&edition=full","pubTime":"2026-01-07 16:03","pubTimestamp":1767772999,"startTime":"0","endTime":"0","summary":"证券之星消息，舒泰神(300204)01月07日在投资者关系平台上答复投资者关心的问题。投资者提问：贵司会有年报业绩预告吗？舒泰神回复：您好！公司预计将于2026年01月31日前发布2025年年度业绩预告。感谢您对公司的关注，谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010700019698.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","300204","BK0239","BK0028"],"gpt_icon":0},{"id":"2601887026","title":"舒泰神（300204）披露拟向银行申请贷款并提供抵押反担保的进展公告（二），1月5日股价上涨5.38%","url":"https://stock-news.laohu8.com/highlight/detail?id=2601887026","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601887026?lang=zh_cn&edition=full","pubTime":"2026-01-05 22:39","pubTimestamp":1767623958,"startTime":"0","endTime":"0","summary":"截至2026年1月5日收盘，舒泰神报收于28.79元，较前一交易日上涨5.38%，最新总市值为137.55亿元。公司近日发布公告称，拟向多家银行申请合计不超过20,000万元人民币贷款，用于公司及下属子公司日常经营周转。公司委托北京亦庄国际融资担保有限公司为上述贷款提供保证担保，并以自有房产及土地使用权作为抵押物向亦庄担保提供反担保，预计担保额度上限不超过30,000万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010500040443.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0028","BK0046","300204","161121"],"gpt_icon":0},{"id":"2600306288","title":"每周股票复盘：舒泰神（300204）股东减持至5%以下持股比例降至4.99%","url":"https://stock-news.laohu8.com/highlight/detail?id=2600306288","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2600306288?lang=zh_cn&edition=full","pubTime":"2026-01-03 01:32","pubTimestamp":1767375132,"startTime":"0","endTime":"0","summary":"舒泰神（北京）生物制药股份有限公司于2025年12月29日发布公告，本次权益变动后，香塘集团及其一致行动人合计持有公司股份2,388.8575万股，占总股本比例由8.26%下降至4.99%，不涉及公司控制权变更，不会对公司治理结构及持续经营产生影响。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010300000199.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0046","BK0028","300204"],"gpt_icon":0},{"id":"2595474947","title":"舒泰神：定增事项正在按流程持续推进中","url":"https://stock-news.laohu8.com/highlight/detail?id=2595474947","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595474947?lang=zh_cn&edition=full","pubTime":"2025-12-31 09:09","pubTimestamp":1767143352,"startTime":"0","endTime":"0","summary":"证券之星消息，舒泰神(300204)12月30日在投资者关系平台上答复投资者关心的问题。投资者提问：贵司定增有进展了吗？舒泰神回复：您好！公司定增事项正在按流程持续推进中，相关进展建议您可查阅公司于2025年12月01日在巨潮资讯网披露的《关于舒泰神（北京）生物制药股份有限公司申请向特定对象发行股票的审核问询函回复及募集说明书等相关文件更新的提示性公告》（公告编号：2025-083）及后续进展公告。感谢您对公司的关注，谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025123100009632.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","300204","BK0239","BK0028"],"gpt_icon":0},{"id":"2595841117","title":"12月29日舒泰神发布公告，股东减持329.61万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2595841117","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595841117?lang=zh_cn&edition=full","pubTime":"2025-12-29 19:01","pubTimestamp":1767006092,"startTime":"0","endTime":"0","summary":"证券之星消息，12月29日舒泰神发布公告《舒泰神:关于持股5%以上股东及其一致行动人减持至5%以下暨权益变动的提示性公告》，其股东香塘集团有限公司于2025年12月12日至2025年12月26日间合计减持329.61万股，占公司目前总股本的0.6899%，变动期间该股股价上涨3.6%，截止12月26日收盘报28.24元。股东增减持详情见下表：根据舒泰神2025年三季报公布的十大股东详情如下：以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122900029098.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","300204","BK0239","BK0046"],"gpt_icon":0},{"id":"2594226714","title":"年度“牛股”：528只翻倍股出炉，AI与并购“双主线”燃爆全场","url":"https://stock-news.laohu8.com/highlight/detail?id=2594226714","media":"第一财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594226714?lang=zh_cn&edition=full","pubTime":"2025-12-28 13:52","pubTimestamp":1766901120,"startTime":"0","endTime":"0","summary":"高居涨幅榜的“牛股”呈现出两大特点：或是AI概念股，或是并购概念股。　　2025年的A股市场就将迎来收官，回首全年，A股市场产生了528只翻倍股，数量是2024年的4倍多。其中，124只个股涨幅超2倍，6只个股超5倍。　　区间涨幅最高的2只个股为上纬新材和天普股份，是按收盘价计算年内唯二的十倍股。　　年内，528只个股年内涨幅超过1倍，翻倍股数量是去年的4倍多。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/roll/2025-12-28/doc-inheirmt1254345.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2025-12-28/doc-inheirmt1254345.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU1064130708.USD","300502","LU1993786604.SGD","LU0577902298.EUR","300025","LU2778985437.USD","LU0880133367.SGD","BK0090","601628","BK0148","BK0070","601318","LU0348805143.USD","605255","159982","300204","301551","399300","002969","LU0128522744.USD","300476","LU1769817096.USD","LU1522347837.USD","AI","HK0000320264.USD","603226","BK0117","LU1226288253.USD","LU2148510915.USD","LU0370786039.SGD","300300","601138","301377","600519","001331","300308","LU1734074674.USD","LU0577902371.SGD","LU2580892862.HKD","002052","002726","600941","301030","600036","688109","688585","LU0620787316.HKD","LU0469268626.HKD","LU0348735423.USD","000592"],"gpt_icon":0},{"id":"2594726076","title":"12月26日舒泰神现1笔折价13.07%的大宗交易 合计成交6226.13万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2594726076","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594726076?lang=zh_cn&edition=full","pubTime":"2025-12-26 17:44","pubTimestamp":1766742256,"startTime":"0","endTime":"0","summary":"证券之星消息，12月26日舒泰神发生大宗交易，交易数据如下：大宗交易成交价格24.55元，相对当日收盘价折价13.07%，成交253.61万股，成交金额6226.13万元，买方营业部为中信证券股份有限公司江苏分公司，卖方营业部为东吴证券股份有限公司太仓上海东路证券营业部。近三个月该股共发生2笔大宗交易，合计成交3.3万手，折价成交2笔。该股近期无解禁股上市。截至2025年12月26日收盘，舒泰神报收于28.24元，上涨2.02%，换手率7.15%，成交量32.46万手，成交额9.12亿元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122600025657.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","300204","BK0028","BK0239"],"gpt_icon":0},{"id":"2591026646","title":"舒泰神：正组织提交STSP-0601补充材料","url":"https://stock-news.laohu8.com/highlight/detail?id=2591026646","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591026646?lang=zh_cn&edition=full","pubTime":"2025-12-15 20:48","pubTimestamp":1765802909,"startTime":"0","endTime":"0","summary":"证券之星消息，舒泰神12月15日在投资者关系平台上答复投资者关心的问题。投资者提问：请问 stsp-0601 补充材料贵司什么时候能提交？公司接到国家药品监督管理局药品审评中心关于注射用STSP-0601项目补充资料的通知后，正在按照通知要求组织相关部门落实并尽快补充提交相关材料，继续推进注射用STSP-0601附条件批准上市工作。此进展不属于《创业板行业信息披露》规则要求的在药品研发、注册过程中应当及时披露的事项，不构成公告事项。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121500032151.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300204","BK0046","BK0239","BK0028"],"gpt_icon":0},{"id":"2589502658","title":"舒泰神：正按CDE要求补充STSP-0601材料","url":"https://stock-news.laohu8.com/highlight/detail?id=2589502658","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589502658?lang=zh_cn&edition=full","pubTime":"2025-12-05 11:48","pubTimestamp":1764906494,"startTime":"0","endTime":"0","summary":"证券之星消息，舒泰神12月04日在投资者关系平台上答复投资者关心的问题。投资者提问：请问董秘，STSP0601新药目前说是需要补充材料，请问CDE具体要求公司补充哪方面的材料，公司估计补充材料大概需要多久完成，投资者有权知道，请正面回复，谢谢舒泰神回复：您好！公司近期收到国家药品监督管理局药品审评中心就STSP-0601项目发出的发补通知。公司高度重视，正在按照通知要求组织相关部门落实并尽快补充提交相关材料。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120500014130.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0028","300204","BK0239"],"gpt_icon":0},{"id":"2589285022","title":"舒泰神：香塘集团计划减持不超过1%股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2589285022","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589285022?lang=zh_cn&edition=full","pubTime":"2025-12-05 11:48","pubTimestamp":1764906491,"startTime":"0","endTime":"0","summary":"证券之星消息，舒泰神12月04日在投资者关系平台上答复投资者关心的问题。根据公司2025年11月05日披露的《关于持股5%以上股东减持股份的预披露公告》，“香塘集团计划自本公告披露之日起15个交易日后的3个月内，即 2025年11月27日至2026年02月26日期间，以大宗交易方式减持股份不超过477.77万股，占公司总股本的1%”。公司将根据相关法规要求，及时履行信息披露义务，敬请关注后续进展公告。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120500014121.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300204","BK0046","BK0028"],"gpt_icon":0},{"id":"2588011519","title":"舒泰神（300204）披露拟向银行申请贷款并提供抵押反担保的进展公告，12月03日股价下跌3.26%","url":"https://stock-news.laohu8.com/highlight/detail?id=2588011519","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588011519?lang=zh_cn&edition=full","pubTime":"2025-12-03 17:02","pubTimestamp":1764752568,"startTime":"0","endTime":"0","summary":"截至2025年12月3日收盘，舒泰神报收于27.59元，较前一交易日下跌3.26%，最新总市值为131.82亿元。公司近日发布公告称，拟向多家银行申请不超过20,000万元人民币贷款，用于公司及下属子公司日常经营周转。公司委托北京亦庄国际融资担保有限公司为上述贷款提供保证担保，并以自有房产及土地使用权提供反担保，预计反担保额度不超过30,000万元。被担保方亦庄担保与公司无关联关系。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120300025587.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0239","161121","300204","BK0046"],"gpt_icon":0},{"id":"2588080520","title":"12月2日舒泰神跌5.31%，易方达医疗保健行业混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2588080520","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588080520?lang=zh_cn&edition=full","pubTime":"2025-12-02 15:33","pubTimestamp":1764660825,"startTime":"0","endTime":"0","summary":"证券之星消息，12月2日舒泰神跌5.31%创60日新低，收盘报28.52元，换手率6.99%，成交量31.71万手，成交额9.11亿元。重仓舒泰神的前十大公募基金请见下表：根据2025基金Q3季报公募基金重仓股数据，重仓该股的公募基金共19家，其中持有数量最多的公募基金为易方达基金的易方达医疗保健行业混合A。易方达医疗保健行业混合A目前规模为38.02亿元，最新净值4.201，较上一交易日下跌0.85%，近一年上涨27.92%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120200017330.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0046","BK0239","300204"],"gpt_icon":0},{"id":"2588702291","title":"舒泰神：BDB-001注射液首例入组已完成","url":"https://stock-news.laohu8.com/highlight/detail?id=2588702291","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588702291?lang=zh_cn&edition=full","pubTime":"2025-12-02 09:02","pubTimestamp":1764637325,"startTime":"0","endTime":"0","summary":"证券之星消息，舒泰神12月01日在投资者关系平台上答复投资者关心的问题。投资者提问：请问贵司的BDB-001注射液的研发进度如何？BDB-001注射液在抗中性粒细胞胞质抗体相关性血管炎方向登记号为CTR20253611的临床试验首例已入组，并已在CDE平台公示。有关研发项目进展，敬请关注后续定期报告及项目进展公告。感谢您对公司的关注，谢谢！","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120200004552.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0046","BK0028","300204"],"gpt_icon":0},{"id":"2586929144","title":"舒泰神：与奥克股份暂无研发方向合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2586929144","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586929144?lang=zh_cn&edition=full","pubTime":"2025-11-27 08:39","pubTimestamp":1764203951,"startTime":"0","endTime":"0","summary":"证券之星消息，舒泰神(300204)11月26日在投资者关系平台上答复投资者关心的问题。投资者提问：奥克股份聚乙二醇取得世界级认证，同时也是公司供货商，请问公司目前与奥克股份有合作聚乙二醇药物深入开发吗舒泰神回复：您好！辽宁奥克药业股份有限公司为公司产品舒泰清原料供应商，公司与辽宁奥克暂无研发方向合作。感谢您对公司的关注，谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112700004237.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0201","BK0155","BK0239","BK0046","300204","BK0028","300082","BK0070","BK0229"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1770556802753,"stockEarnings":[{"period":"1week","weight":0.0842},{"period":"1month","weight":-0.0566},{"period":"3month","weight":-0.1813},{"period":"6month","weight":-0.4425},{"period":"1year","weight":2.9349},{"period":"ytd","weight":0.0183}],"compareEarnings":[{"period":"1week","weight":-0.0127},{"period":"1month","weight":-0.0049},{"period":"3month","weight":0.017},{"period":"6month","weight":0.1184},{"period":"1year","weight":0.243},{"period":"ytd","weight":0.0244}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"舒泰神(北京)生物制药股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"46538人(较上一季度增加46.97%)","perCapita":"9748股","listingDate":"2011-04-15","address":"北京市大兴区北京经济技术开发区经海二路36号","registeredCapital":"47777万元","survey":"　　舒泰神(北京)生物制药股份有限公司的主营业务是生物药物的研发、生产和营销。公司的主要产品是创新生物药物苏肽生（注射用鼠神经生长因子）、特色品种舒泰清（复方聚乙二醇电解质散（IV））。","listedPrice":52.5},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"舒泰神(300204)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供舒泰神(300204)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"舒泰神,300204,舒泰神股票,舒泰神股票老虎,舒泰神股票老虎国际,舒泰神行情,舒泰神股票行情,舒泰神股价,舒泰神股市,舒泰神股票价格,舒泰神股票交易,舒泰神股票购买,舒泰神股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"舒泰神(300204)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供舒泰神(300204)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}